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ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not, “Is the 
use of laser therapy an effective alternative treatment for women with fibromyalgia?” 
 
STUDY DESIGN: Review of three English language primary studies, published between 2002 
and 2013.  
 
DATA SOURCES:  Three randomized controlled trials (RCTs) were found using Cochrane 
Systematic Reviews. These studies analyzed the effectiveness of laser therapy in women with 
fibromyalgia.  
 
OUTCOMES MEASURED:  Main outcomes measured were improvement in pain, number of 
tender points, muscular spasm, skinfold tenderness, sleep disturbance, fatigue and morning 
stiffness measured by an ordinal likert scale, Pain and FM impact measured by the FM Impact 
Questionnaire (FIQ), Body flexibility measured by the continuous scale physical functional 
performance test (CS-PFP), number of tender points measured by distal palpation, and well 
being measured by the verbal scale of global evaluation by the patient concerning her well-being 
(VSGI). P-values were used to assess the significance of the outcomes.  
 
RESULTS: All three studies showed significant improvement in the functioning of women with 
fibromyalgia. In the Panton et all study, it was shown that there were improvements in pain, 
upper body flexibility, and FM impact. The Gur et all study showed improvements in pain, 
muscle spasm, morning stiffness, and total tender point number, and the Armagan et al study 
showed improvements in the FIQ, VSGI, and total myalgia after laser therapy.  
CONCLUSION: The results of three RCTs which compared before and after laser treatment 
groups to before and after placebo laser therapy groups showed laser therapy to be an effective 
treatment for women with fibromyalgia.  
KEY WORDS: Fibromyalgia, Laser therapy.  
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INTRODUCTION 
Fibromyalgia is a rheumatologic disorder characterized mainly by widespread chronic 
body pain.5 The American College of Rheumatology goes on to define the diagnosis as pain in 
three out of four of the body quadrants for at least a duration of three consecutive months as well 
as tenderness with palpation at eleven or more out of eighteen of specific tender points.5 
Although pain is the most common complaint, fibromyalgia patients commonly report insomnia, 
fatigue, headaches, irritable bowel syndrome, morning stiffness, parenthesias, anxiety, and 
depression.1   
Fibromyalgia is considered the second most common rheumatologic disorder in the 
United States in that it is found in approximately four to six million people.5 In total, it is said to 
affect about 3% of the female population but it has also been found to occur in both men and 
children.1 Additionally, women tend to be diagnosed with the disorder between the ages of 20 
and 50 but the prevalence does increase with age.5 By the age of 80, 8% of women are diagnosed 
with fibromyalgia.5  
Due to the commonality of the disorder, there is a definite economic burden in the United 
States due to heath care costs pertaining to fibromyalgia patients. The total annual cost to the 
United States economy is twelve to fourteen billion dollars.7 In addition, 34% of all fibromyalgia 
patients tend to spend between $100 and $1,000 per month above what their insurance will cover 
in order to be seen and treated by a healthcare professional in their times of need.5 The average 
fibromyalgia patient a goes to see a healthcare professional thirteen times per year.6  
Although fibromyalgia is a rather common disorder, research has yet to discover the 
exact cause leading to its development. It is, however, thought that central sensitization is the 
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main mechanism involved, as well as many other components such as genetic predisposition, 
environmental stressor exposure, alterations in sleep architecture, hypothalamic-pituitary adrenal 
axis alterations, and autonomic nervous systems alterations. Genetics are thought to be involved 
in the disorder because there is a strong familial link. Patients with the diagnosis had an eight 
times greater chance of a first-degree relative having the diagnosis as well. The environmental 
triggers that are thought to be involved are a prior history of trauma or abuse, as well as infection 
and psychological stress. In terms of alteration of the sleep cycle, it is thought that patients with 
fibromyalgia are experiencing intermittent arousal from the brain, leading to constant 
interruption of their deepest and most refreshing sleep. Lastly, the hypothalamic-pituitary-
adrenal axis and autonomic nervous systems alterations seem to play a role in the development 
of the disorder because studies have shown that patients have a higher heart rate at rest as well as 
less variability in their heart rate throughout the day.7   
In addition to the multiple contributing factors to the development of fibromyalgia, there are 
also multiple modalities used for treatment and comfort in patients with fibromyalgia. Firstly, the 
typical pharmacologic interventions utilized are tricyclic antidepressants, serotonin antagonists, 
nonsteroidal anti-inflammatory drugs, anti-epileptic drugs, sedatives, muscle relaxants, and opiates.5 
Secondly, alternative interventional techniques such as trigger point injections, massage therapy, 
exercise, physical therapy, electrotherapy, and biofeedback training have also been used in 
treatment.1 Typically, patients will use multiple management techniques in order to control their pain 
level as much as possible.1 
While these treatments have been shown to somewhat alleviate the pain, their use for 
treatment has been limited and there is currently no complete cure for the condition.1 It has been 
shown that pharmacologic therapy has achieved successful improvement in only 50% of patients, as 
well as leading to many side-effects such as weight gain, morning drowsiness, abdominal pain, and 
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increased tolerance to the treatment overtime.5 It is also shown that 47% of the women with 
fibromyalgia are nonadherent with their medications.5 For these reasons, alternative interventions 
such as laser therapy have shown an increase in popularity among patients and may be used to help 
relieve the symptoms of fibromyalgia.5 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not, “Is the use of 
laser therapy an effective alternative treatment for women with fibromyalgia?” 
METHODS 
The population of the studies used for this review includes women with fibromyalgia. Their 
ages ranged from 33 to 64. One of the studies involved in the review used class IV laser therapy, one 
used class III b laser therapy, and the other one used low-level energy laser therapy. The comparison 
groups were given sham laser therapy that was a visually matched placebo. The different outcomes 
measured in the studies included improvement in pain, number of tender points, muscular spasm, 
skinfold tenderness, sleep disturbance, fatigue, morning stiffness, FM impact, body flexibility, 
and well-being. All three studies were randomized controlled trials that compared laser therapy to 
placebo laser therapy.  
The author, using the key words “fibromyalgia” and “laser therapy, carried out a detailed 
search using the Cochrane Systematic Review and PubMed. Each of the articles was published in 
English and in peer-reviewed journals. Each of the articles was selected based on their relevance to 
the clinical question as well as their evidence falling in the category of a POEM.  Inclusion criteria 
consisted of articles that involved randomly controlled trials published after 2000. Studies excluded 
were those that involved male participants. The statistic that was reported in the three studies was a 
p-value with a p ≤ .05 deemed statistically significant. Table 1 displays the demographics and 
characteristics of these three articles. 
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Table 1: Demographics & Characteristics of included studies 
Study  Type  #pts Age 
(yrs) 
Inclusion 
criteria 
Exclusion criteria W/D Interventions 
(Panton)5 
2013 
Double 
blind 
RCT 
38 52 
±11 
yrs  
 
Female  
At least 11 
out of 18 
tender 
points. 
Uncontrolled 
hypertension/ DM, 
Active heart disease, 
history of cancer, Long 
term steroid use, 
Pregnant, Endocrine 
disease, anticoagulation, 
bleeding disorders, 
stroke, chronic infection, 
malignancy, taking 
medication that causes 
photosensitivity, 
contraindication to light 
or thermal therapy, under 
the care of a chiropractic 
physician, acupuncture 
physician, massage 
therapist, or other forms 
of manual therapy.  
3 Class IV laser 
therapy  
 
(Gur)2 
2002 
Single 
blind 
RCT 
40 40 
±15 
yrs  
 
Female  
At least 11 
out of 18 
tender 
points 
Widespread 
pain for 3 
months 
A recent or past history 
of psychiatric disorders, 
Immunocompromised 
subjects, Subjects with 
neurological, 
inflammatory, endocrine 
or clinically, significant 
chronic disease, 
Abnormal liver function 
tests, Pregnancy  
0 Low power laser 
therapy  
 
(Armagen) 
1 2006 
Single 
blind 
RCT 
32 38.94 
± 4.85  
 
Female 
Widespread 
pain for at 
least 3 
months on 
both sides 
of body, 
above and 
below the 
waist.  
At least 11 
tender 
points  
Inflammatory cause of 
pain; Inability to interrupt 
therapy with analgesic, 
anti-inflammatory 
medications, 
antidepressants, sleeping/ 
central nervous system-
active 
drugs;neurological, 
inflammatory, endocrine, 
or chronic disease, such 
as IBD, rheumatoid 
arthritis, lupus, or DM; 
Severe disease such as a 
tumor, liver, renal 
disease; Pregnancy; 
major psychiatric 
disorders.  
0 Low level laser 
therapy  
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OUTCOMES MEASURED 
 Each outcome measured was a POEM and was measured in a variety of ways. Firstly, 
Gur et al measured the outcomes of improvement in pain, number of tender points, skinfold 
tenderness, morning stiffness, sleep disturbance, muscular spasm, and fatigue using an ordinal 
likert scale. The categories on the scale were, No (0), moderate (1), severe (3), and extreme (4).  
Panton et al used multiple methods to measure the chosen outcomes of tender-point 
sensitivity, the Fibromyalgia Impact Questionnaire (FIQ), and functionality. Firstly, at the 
participants initial visit as well as after their four week long treatment, they had a tender points 
assessment performed by a rheumatologist who then decided on their number of tender points, as 
well as rating those points on a sensitivity scale from 0, meaning no pain, to 3, meaning 
withdrawal of patient from examiner. The FM Impact Questionnaire (FIQ) was also used as an 
outcome to measure the impact that the disorder had on their quality of life. The FIQ is able to 
measure physical functioning in activities of daily living, general-well being of the patient, as 
well as fibromyalgia related-symptoms like pain and body flexibility. Lastly, the Continuous 
Scale Physical Functional Performance (CS-PFP) test was used revealing the participant’s level 
of physical functioning. This test simulates different tasks of common daily activities. At the 
completion of the four-week intervention, participants repeated the testing that was completed in 
the initial visit again. The investigators who measured tender-point sensitivity, FIQ, and 
functionality were blinded to the group assignment of the participants.5 
Lastly, Armagen et al used multiple methods to study their outcomes as well. Number of 
tender points was measured using digital palpation. The point was recorded as tender if the 
patient reported it upon palpation.  Morning stiffness was measured using an ordinal Likert scale 
defined as no (0), mild (1), moderate (2), severe (3), and extreme (4).  This study also used the 
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Fibromyalgia Impact Questionnaire (FIQ) and the Verbal scale of global evaluation by the 
patient concerning her well-being (VSGI). The VSGI created a score from 1 to 5 in which 1 
means great improvement, 2 means moderate improvement, 3 means slight improvement, 4 
means no improvement, and 5 means worsening. A Total myalgia score was then created through 
response to a digital force of 4 kg after which the participants said whether they felt no 
discomfort (0 points), tenderness (1 point), pain without grimace, flinching, or withdrawal (2 
points), or pain with grimace, flinching, or withdrawal (3 points).1 
RESULTS 
Armagon et al included 32 female patients ages 26 to 47 in the trial. All 32 of them 
carried out the entirety of the study. All patients received treatments once a day, five days a 
week, for a total duration of ten days. The laser beam was applied to each tender point for one 
minute and the same physician treated all of the patients. All of the patients in the study, whether 
in the laser treatment or placebo group, had similar conditions prior to treatment. In the laser 
treatment group, participants showed significant improvements in all categories measured after 
laser therapy. Tender point number decreased by an average of 1.87, morning stiffness decreased 
by an average of .62, VSIQ score decreased by an average of .88, FIQ scores decreased by an 
average of 7, and total myalgia scores decreased by an average of 5.5. For these scores, P < 0.05. 
On the contrary, the only categories in which significant improvement could be seen in those 
treated with placebo laser therapy were number of tender points and morning stiffness. Tender 
point number decreased by an average of 1.06 and morning stiffness decreased by an average of 
.56. In these two categories, P < 0.05. These results can be seen in table 2. There were no 
systemic or local side effects that were reported during or after the treatment period in either 
group of participants.1
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Table 2: Mean	  change	  from	  baseline, Armagon et al 1 
 Tender 
points 
Morning 
stiffness 
VSIQ score FIQ score Total 
Myalgia 
Laser 
therapy  
-1.87* -.62* -.88* -7* -5.5* 
Sham laser 
therapy  
-1.06* -.56* -.19 -1.75 -1.56 
* p <.05 
Gur et all included 40 females with fibromyalgia. All patients carried out the entirety of 
the study. Each patient experienced a two-week treatment period of five days per week for a total 
of ten treatments. The laser therapy included three minutes of treatment on each tender point. 
Prior to the treatment, the two groups showed no significant difference in any of the categories 
studied when compared to each other. However, significant changes in all categories were seen 
in those participating in the actual laser therapy group. Pain improved by an average of 1.82, 
skinfold tenderness improved by an average of 1.28, muscle spasm improved by an average of 
1.46, morning stiffness improved by an average of 1.45, tender point number improved by an 
average of 6.55, sleep disturbance improved by an average of 1.09, and fatigue improved by an 
average of 1.73. For these values p<0.05. On the contrary, the placebo group only showed 
significant improvement in pain, muscle spasm, morning stiffness, and tender point number. Pain 
improved by an average of 1.0, muscle spasm improved by an average of .9, morning stiffness 
improved by an average of .69, tender point number improved by an average of 4.15. For these 
values p<0.05. These results are shown in table 3.  None of the participants in the study reported 
increased discomfort as a result of their treatment or an increase in any of the measured 
outcomes, whether they received the laser or the placebo therapy.2
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Table 4. Mean	  change	  from	  baseline,	  Gur	  et	  al2	  
	  
	  
	  
	  
          
*p <.05 
The Panton et al study included 42 women with fibromyalgia, 38 of whom completed the 
entirety of the study. One woman did not follow up after the initial assessments, two women did 
not return due to scheduling conflict, and a final woman could not complete the study due to 
major depressive disorder. In order for this study to make the two groups appear to have the 
same treatment, the treatment group was given laser and heat therapy, while the placebo group 
was given sham and heat therapy. Both groups had treatment twice each week for four weeks, 
totaling in eight treatments. When looking at the baseline statistics alone, the treatment and 
control groups did not significantly differ.  Of the different outcomes measured in the laser and 
heat therapy group, significant improvement resulted in total tender points, myalgic score, pain, 
upper body flexibility, and the CS-PFP score. Total tender points decreased by an average of 3, 
myalgic score decreased by an average of 3, pain decreased by an average of .9, upper body 
flexibility increased by an average of 7, and CS-PFP score increased by an average of 7. In order 
to show significance in these numbers, p<0.05. On the other hand, the group that received sham 
and heat treatment showed significant changes in only the number of tender points, myalgic 
score, and CS-PFP score. Number of tender points decreased by an average of 3, myalgic score 
decreased by an average of 3, and CS-PFP scores increased by an average of 4.  These results 
can be seen in table 5.5
 Pain Skinfold 
tenderness 
Muscle 
spasm 
Morning 
stiffness 
Tender 
points 
Sleep 
disturbance 
Fatigue 
Laser 
therapy  
-1.82* -1.28* -1.46* -1.45* -6.55* -1.09* -1.73* 
Sham laser 
therapy  
-1.0* -.77 -.9* -.69* -4.15* -.04 -.06 
Astrove,	  Laser	  Therapy	  and	  Fibromyalgia	  	  	  	  	  9	  
Table 5. Mean change from baseline, Panton et al5  
 Tender 
points 
Myalgic 
score 
Pain Upper body 
flexibility 
CS-PFP 
Laser 
therapy  
-3* -3* -.9* 7* 7* 
Sham laser 
therapy  
-3* -3* .3 0 -4* 
* p <.05 
DISCUSSION 
 The three randomized controlled trials discussed in this review suggest that laser therapy 
is an effective alternative treatment for fibromyalgia. All three studies demonstrated a 
statistically significant reduction in at least two of the outcomes measured with a statistical 
significance threshold set at p ≤ .05.  One other study conducted by Gur et al compared laser 
therapy to sham laser therapy as well as the traditionally used Amytriptyline. This study showed 
that the laser therapy was above all else in terms of decreasing pain intensity, fatigue, morning 
stiffness, FIQ score, and depression score, which shows great promise for the use of laser therapy 
in fibromyalgia treatment.1  
 The Panton et al study showed the least positive difference when comparing the 
experimental and control groups, but there are a few possible explanations for this contradiction 
to the other two studies. This study decided that in order to make the control and experimental 
groups similar enough, both groups would require heat application to the treated area. Since heat 
has been shown to have some therapeutic properties in the treatment of fibromyalgia, this would 
explain the improvement in the outcomes of the control group. However, since the women that 
received the laser as well as heat therapy showed additional positive outcomes as well as a 
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greater difference in the outcomes when compared to the control group, this study still suggests 
that laser therapy is an effective alternate treatment for fibromyalgia.5 
On the other hand, it is important to note that there are still many limitations regarding 
laser therapy as a treatment mechanism in that literature laser treatment has been inconsistent and 
disorganized.2 Information surrounding the specificities of the laser treatment parameters such as 
the optimal dose, intensity, frequency, wavelength, and peak that should be used, as well as the 
best mode of delivery, is still unknown.1 There are also different treatment techniques such as 
irradiating one single point or sweeping across it. One technique has not yet been shown to be 
more effective than the others.2 Additionally, it is unknown if certain parameters must be altered 
based on the specific areas to be irradiated and diagnosis of the person being treated. These 
parameters could include the minimally effective dose, duration, number, and schedule of the 
treatment.1 The different bodily tissues on the body may have different absorption spectra and 
could respond in a different manner to the laser.2 As a result of these various unknowns about the 
use of laser therapy as a treatment method, further clinical evaluation and research is needed. 
Research is also needed to provide information on when the treatment should be terminated and 
how long the benefits will last.  
Laser therapy continues to be used for treatment in many disciplines. The FDA has 
approved the usage of low-level laser therapy, however, there are some contraindications to its 
usage.3 Currently, known contraindications include a history of malignant carcinoma, radiation 
in the thyroid region, epilepsy, exposure of the retina during treatment, and pregnancy.4 
Additionally, most insurance companies do not typically cover laser therapy, but as research on 
its treatment for fibromyalgia continues, there is hope of future coverage for patients.3
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CONCLUSION 
 Laser therapy is an effective treatment alternative for women with fibromyalgia. 
The three randomized controlled trials discussed in this review showed improvement in 
outcomes measured after the application of laser therapy. Based on these results, low-level laser 
therapy should be considered as monotherapy or as an additional supplement to other treatment 
modalities in women with fibromyalgia.  
Despite this convincing evidence, additional research needs to be done in order to answer 
questions about the best treatment protocol in terms of scheduling, wavelength, frequency, and 
intensity, as well as deducing whether different areas of a patient’s body will require different 
protocols. Additional research should also be completed to compare currently used therapeutic 
treatment regimens to the laser therapy, as well as comparing whether monotherapy or 
polytherapy would be most cost effective. Lastly, additional research is needed to decide if there 
are long-term benefits to each laser therapy treatment or if the laser treatments will have to be 
continued on a life-long basis.  
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